MA41788A - Modulation de l'immunité tumorale par proteines médiatrices de la délivrance d'o2 - Google Patents
Modulation de l'immunité tumorale par proteines médiatrices de la délivrance d'o2Info
- Publication number
- MA41788A MA41788A MA041788A MA41788A MA41788A MA 41788 A MA41788 A MA 41788A MA 041788 A MA041788 A MA 041788A MA 41788 A MA41788 A MA 41788A MA 41788 A MA41788 A MA 41788A
- Authority
- MA
- Morocco
- Prior art keywords
- mediatory
- proteins
- modulation
- delivery
- tumor immunity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1092—Details
- A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562134523P | 2015-03-17 | 2015-03-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA41788A true MA41788A (fr) | 2021-03-31 |
Family
ID=56297072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA041788A MA41788A (fr) | 2015-03-17 | 2016-03-17 | Modulation de l'immunité tumorale par proteines médiatrices de la délivrance d'o2 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20180243364A1 (fr) |
| EP (1) | EP3270961A2 (fr) |
| JP (2) | JP7049832B2 (fr) |
| KR (1) | KR20170132789A (fr) |
| CN (1) | CN107580499A (fr) |
| AU (1) | AU2016232866B2 (fr) |
| BR (1) | BR112017019862A2 (fr) |
| CA (1) | CA2979974A1 (fr) |
| HK (2) | HK1249416A1 (fr) |
| IL (1) | IL254507B (fr) |
| MA (1) | MA41788A (fr) |
| MX (1) | MX2017011847A (fr) |
| RU (1) | RU2731450C2 (fr) |
| SG (2) | SG10201908269SA (fr) |
| WO (1) | WO2016149562A2 (fr) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10385116B2 (en) * | 2013-01-07 | 2019-08-20 | Omniox, Inc. | Polymeric forms of H-NOX proteins |
| CN109414426B (zh) * | 2016-07-05 | 2024-12-20 | 北极星药业集团股份有限公司 | 使用精氨酸耗竭剂的组合癌症免疫疗法 |
| WO2020037052A1 (fr) * | 2018-08-15 | 2020-02-20 | Omniox, Inc. | Protéines h-nox pour le traitement d'affections cardiovasculaires et pulmonaires |
| CN114245807A (zh) | 2019-06-25 | 2022-03-25 | 吉利德科学公司 | Flt3l-fc融合蛋白和使用方法 |
| JP7371243B2 (ja) | 2019-10-18 | 2023-10-30 | フォーティ セブン， インコーポレイテッド | 骨髄異形成症候群及び急性骨髄性白血病を治療するための併用療法 |
| MX2022005123A (es) | 2019-10-31 | 2022-05-30 | Forty Seven Inc | Tratamiento basado en anti-cd47 y anti-cd20 para cancer hematologico. |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| AU2020412875A1 (en) | 2019-12-24 | 2022-06-23 | Carna Biosciences, Inc. | Diacylglycerol kinase modulating compounds |
| US11692038B2 (en) | 2020-02-14 | 2023-07-04 | Gilead Sciences, Inc. | Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8) |
| KR20230006891A (ko) | 2020-05-01 | 2023-01-11 | 길리애드 사이언시즈, 인코포레이티드 | Cd73를 억제하는 2,4-다이옥소피리미딘 화합물 |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| US20240139280A1 (en) * | 2021-04-14 | 2024-05-02 | OncoC4, Inc. | Use of hif-1-alpha inhibitors in cancer immunotherapy |
| US20220389394A1 (en) | 2021-05-18 | 2022-12-08 | Gilead Sciences, Inc. | METHODS OF USING FLT3L-Fc FUSION PROTEINS |
| US11999733B2 (en) | 2021-06-23 | 2024-06-04 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| US11926628B2 (en) | 2021-06-23 | 2024-03-12 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| EP4359415A1 (fr) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Composés modulant les diacylglycérol kinases |
| CA3220923A1 (fr) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Composes de modulation de la diacylglycerol kinase |
| KR20240091056A (ko) | 2021-10-28 | 2024-06-21 | 길리애드 사이언시즈, 인코포레이티드 | 피리디진-3(2h)-온 유도체 |
| CN118201941A (zh) | 2021-10-29 | 2024-06-14 | 吉利德科学公司 | Cd73化合物 |
| CN118488948A (zh) | 2021-12-22 | 2024-08-13 | 吉利德科学公司 | Ikaros锌指家族降解剂及其用途 |
| CN118488946A (zh) | 2021-12-22 | 2024-08-13 | 吉利德科学公司 | Ikaros锌指家族降解剂及其用途 |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| US20230373950A1 (en) | 2022-03-17 | 2023-11-23 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| WO2023183817A1 (fr) | 2022-03-24 | 2023-09-28 | Gilead Sciences, Inc. | Polythérapie pour le traitement de cancers exprimant trop -2 |
| WO2023196784A1 (fr) | 2022-04-05 | 2023-10-12 | Gilead Sciences, Inc. | Combinaisons de thérapies par anticorps pour traiter le cancer colorectal |
| AU2023256670A1 (en) | 2022-04-21 | 2024-10-17 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2023235716A2 (fr) * | 2022-05-31 | 2023-12-07 | Cardiff Oncology, Inc. | Traitement du cancer à l'aide d'inhibiteurs de topoisomérase i et d'inhibiteurs de plk1 |
| WO2024006929A1 (fr) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Composés cd73 |
| US20240091351A1 (en) | 2022-09-21 | 2024-03-21 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY |
| WO2024137852A1 (fr) | 2022-12-22 | 2024-06-27 | Gilead Sciences, Inc. | Inhibiteurs de prmt5 et leurs utilisations |
| WO2024215754A1 (fr) | 2023-04-11 | 2024-10-17 | Gilead Sciences, Inc. | Composés modulateurs de kras |
| WO2024220917A1 (fr) | 2023-04-21 | 2024-10-24 | Gilead Sciences, Inc. | Inhibiteurs de prmt5 et leurs utilisations |
| US20250042922A1 (en) | 2023-06-30 | 2025-02-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| WO2025024811A1 (fr) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Inhibiteurs de parp7 |
| US20250066328A1 (en) | 2023-07-26 | 2025-02-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025054530A1 (fr) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Dérivés polycycliques contenant une pyrimidine utilisés comme composés de modulation de kras g12d |
| WO2025054347A1 (fr) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Composés de modulation de kras g12d |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5295944A (en) * | 1991-05-14 | 1994-03-22 | Dana-Farber Cancer Institute | Method for treating a tumor with ionizing radiation |
| WO2002012332A2 (fr) * | 2000-08-07 | 2002-02-14 | Corixa Corporation | Compositions et procedes pour la therapie et le diagnostic du cancer du colon |
| US20050176108A1 (en) * | 2003-03-13 | 2005-08-11 | Young-Min Kim | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
| WO2007139767A2 (fr) * | 2006-05-22 | 2007-12-06 | The Regents Of The University Of California | Préparations et méthodes pour la libération d'oxyde nitrique |
| US20110288023A1 (en) * | 2007-06-08 | 2011-11-24 | The Regents Of The University Of California Office Of Technology Transfer | Cancer drug delivery using modified transferrin |
| US20100183545A1 (en) * | 2008-10-14 | 2010-07-22 | The United States Of America, As Represented By The Secretary, | Targeted cargo protein combination therapy |
| JP2011168521A (ja) * | 2010-02-18 | 2011-09-01 | Eci Inc | ＰＥＧ化ｅＭＩＰ及びその製造方法並びにこれを用いた癌治療剤 |
| US7989593B1 (en) * | 2010-05-27 | 2011-08-02 | Bing Lou Wong | Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof |
| US10385116B2 (en) * | 2013-01-07 | 2019-08-20 | Omniox, Inc. | Polymeric forms of H-NOX proteins |
| WO2014182761A1 (fr) * | 2013-05-09 | 2014-11-13 | Mayo Foundation For Medical Education And Research | Traitement de patients en fonction des sous-types immunitaires |
| WO2014193898A1 (fr) * | 2013-05-31 | 2014-12-04 | Merck Sharp & Dohme Corp. | Thérapies combinées contre le cancer |
| JOP20200094A1 (ar) * | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
-
2016
- 2016-03-17 MA MA041788A patent/MA41788A/fr unknown
- 2016-03-17 SG SG10201908269S patent/SG10201908269SA/en unknown
- 2016-03-17 JP JP2017549034A patent/JP7049832B2/ja active Active
- 2016-03-17 US US15/558,957 patent/US20180243364A1/en not_active Abandoned
- 2016-03-17 IL IL254507A patent/IL254507B/en unknown
- 2016-03-17 RU RU2017134953A patent/RU2731450C2/ru active
- 2016-03-17 EP EP16734059.5A patent/EP3270961A2/fr active Pending
- 2016-03-17 MX MX2017011847A patent/MX2017011847A/es unknown
- 2016-03-17 CA CA2979974A patent/CA2979974A1/fr active Pending
- 2016-03-17 WO PCT/US2016/022981 patent/WO2016149562A2/fr active Application Filing
- 2016-03-17 KR KR1020177029648A patent/KR20170132789A/ko not_active Application Discontinuation
- 2016-03-17 SG SG11201707583RA patent/SG11201707583RA/en unknown
- 2016-03-17 CN CN201680027143.9A patent/CN107580499A/zh active Pending
- 2016-03-17 BR BR112017019862A patent/BR112017019862A2/pt active IP Right Grant
- 2016-03-17 AU AU2016232866A patent/AU2016232866B2/en active Active
-
2018
- 2018-07-10 HK HK18108922.6A patent/HK1249416A1/zh unknown
- 2018-07-20 HK HK18109475.5A patent/HK1250137A1/zh unknown
-
2020
- 2020-08-04 JP JP2020132260A patent/JP2020183450A/ja active Pending
-
2021
- 2021-12-10 US US17/547,748 patent/US20220160823A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SG10201908269SA (en) | 2019-10-30 |
| HK1250137A1 (zh) | 2018-11-30 |
| RU2017134953A3 (fr) | 2019-12-26 |
| US20220160823A1 (en) | 2022-05-26 |
| BR112017019862A2 (pt) | 2018-05-29 |
| AU2016232866A1 (en) | 2017-10-12 |
| KR20170132789A (ko) | 2017-12-04 |
| JP7049832B2 (ja) | 2022-04-07 |
| CN107580499A (zh) | 2018-01-12 |
| US20180243364A1 (en) | 2018-08-30 |
| JP2020183450A (ja) | 2020-11-12 |
| WO2016149562A3 (fr) | 2016-11-03 |
| RU2017134953A (ru) | 2019-04-08 |
| WO2016149562A2 (fr) | 2016-09-22 |
| CA2979974A1 (fr) | 2016-09-22 |
| IL254507B (en) | 2022-07-01 |
| HK1249416A1 (zh) | 2018-11-02 |
| JP2018511595A (ja) | 2018-04-26 |
| IL254507A0 (en) | 2017-11-30 |
| SG11201707583RA (en) | 2017-10-30 |
| EP3270961A2 (fr) | 2018-01-24 |
| AU2016232866B2 (en) | 2021-10-21 |
| RU2731450C2 (ru) | 2020-09-03 |
| MX2017011847A (es) | 2018-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA41788A (fr) | Modulation de l'immunité tumorale par proteines médiatrices de la délivrance d'o2 | |
| EP3317294A4 (fr) | Peptides stabilisés anti-microbiens | |
| MA47323A (fr) | Protéines de liaison icos | |
| EP3730094C0 (fr) | Système de pose de prothèse de valvule cardiaque | |
| EP3370760A4 (fr) | Thérapie de substitution de plasminogène destinée au déficit en plasminogène | |
| EP3307378A4 (fr) | Thérapie de modulation intratumorale | |
| FR3018450B1 (fr) | Procede de preparation de proteines plasmatiques humaines | |
| HUE053347T2 (hu) | Glikopeptid-készítmények | |
| DK3474802T3 (da) | Medicinsk forbinding | |
| FR3040468B1 (fr) | Lampe | |
| EP3392552A4 (fr) | Lampe | |
| EP3355931C0 (fr) | Conjugués de protéines | |
| MA56416A (fr) | Détermination de la pureté de protéines multimériques | |
| HUE063435T2 (hu) | Eljárások rekombináns fehérjék mannóztartalmának növelésére | |
| EP3436049A4 (fr) | Protéine 8 de type angiopoïétine (angptl8) | |
| DK3259358T3 (da) | Forøget proteinekspression | |
| DK3702450T3 (da) | Protein | |
| DK3615169T3 (da) | Separeringslegeme | |
| EP3463414C0 (fr) | Interfaces de protéines | |
| EP3377633C0 (fr) | Production de protéines recombinantes | |
| DK3615931T3 (da) | Separeringslegeme | |
| ZA201902689B (en) | Therapeutic protein | |
| DK3099793T3 (da) | Protein | |
| DK3274447T3 (da) | Rekombinant fåresygevirus jeryl lynn 2 baseret vaccine | |
| IL250531B (en) | Efficient selectivity of recombinant proteins |